Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine in Neuroblastoma
NCT02163356Phase 1Terminated
- Sponsor
- South Plains Oncology Consortium
- Start
- May 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fenretinide in neuroblastoma, sponsored by South Plains Oncology Consortium. Primary endpoints: Maximum Tolerated Dose at 21 days, Side effect profile of drug combination at 21 days and 1 more. Started May 2014; status: terminated.
02
Drugs
fenretinide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02163356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163356.